Novo Nordisk selects AWS as strategic partner to accelerate drug discovery with AI
Industries Blog
This article announces Novo Nordisk's strategic partnership with AWS to accelerate drug discovery and modernize operations through AI and cloud technologies.
- AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner
- Co-innovation hub established at Novo Nordisk's King's Cross facility in London
- Hub brings together Novo Nordisk scientists with AWS Forward Deployed Engineering and Professional Services teams
- Novo Nordisk will use Amazon Bio Discovery for AI-powered drug candidate generation and evaluation
- Amazon Bedrock AgentCore enables building production-grade AI agents for multi-step workflows
- Over 25,000 Novo Nordisk employees already use Amazon Bedrock for productivity applications
The partnership combines Novo Nordisk's therapeutic expertise with AWS's cloud and AI services to compress drug discovery timelines and eliminate silos between research, engineering, and clinical teams.
The AWS News Feed is currently looking for gold sponsors. If you want to support the AWS community and reach a large audience of AWS professionals, consider sponsoring the AWS News Feed.
Related articles
Oct 7
2024
2024
Accelerating Drug Discovery with AWS HealthOmics and NVIDIA Blueprints
Jul 27
2026
2026
Kite Advances Scalable Bioinformatics for Cell Therapy Research in Collaboration with AWS HealthOmics
Nov 19
2025
2025
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service
Apr 19
2024
2024
Scale AI training and inference for drug discovery through Amazon EKS and Karpenter
The AWS News Feed is currently looking for silver sponsors. If you want to support the AWS community and reach a large audience of AWS professionals, consider sponsoring the AWS News Feed.